<DOC>
	<DOC>NCT00803712</DOC>
	<brief_summary>Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis</brief_summary>
	<brief_title>20070360 Incident Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism, Secondary</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Adults greater than or equal to 18 years of age on hemodialysis for &gt; 3 and less than or equal to 12 months prior to enrollment into the study Mean of 2 PTH determinations during the screening period (drawn at least 2 days apart) &gt; 300 pg/mL (31.8 pmol/L); or biPTH &gt; 160 pg/mL (17.0 pmol/L) Mean of 2 corrected serum calcium determinations drawn on the same day as the PTH determinations greater than or equal to 8.4 mg/dL (2.1 mmol/L) Subject will be able to complete the study, to the best of his/her knowledge Before any studyspecific procedure, the appropriate written informed consent must be obtained Mean of 2 PTH determinations during the screening period (drawn at least 2 days apart) &gt; 800 pg/mL (84.9 pmol/L); or biPTH &gt; 430 pg/mL (45.6 pmol/L) AND receiving vitamin D on entering screening Parathyroidectomy (partial or full) less than or equal to 6 months before entering screening Anticipated parathyroidectomy (partial or full) within 6 months after randomization Have a scheduled date for kidney transplant surgery Received cinacalcet since initiating hemodialysis Have received vitamin D therapy for less than 30 days before entering screening or required a change in prescribed vitamin D brand or dose within 30 days before entering screening. If subjects are not receiving vitamin D therapy, they must remain free of vitamin D therapy for the 30 days before entering screening Subject is pregnant (eg, positive HCG test) or is breastfeeding Refusal to use highly effective contraceptive measures (as determined by the investigator) throughout the study (screening and post enrollment) Current gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets Known sensitivity, intolerance, or other adverse response to cinacalcet which would prevent onstudy treatment compliance Have an unstable medical condition within 30 days before screening, or otherwise unstable in the judgment of the investigator Subject is currently enrolled in, or fewer than 30 days prior to entering screening have passed since subject received other investigational agent(s) (devices or drug).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>